Bidirectional Mendelian Randomization Analysis of the Association between Telomere Length and the Risk of Vascular Dementia and Idiopathic Normal Pressure Hydrocephalus

Wencai Wang

doi:10.71423/aimed.20251209

PDF Supplementary Table 1 (XLSX) Supplementary Table 2 (XLSX)

Submitted: 2025-09-06

Accepted: 2025-12-02

Published: 2025-12-09

DOI: https://doi.org/10.71423/aimed.20251209

Keywords:

telomere length, vascular dementia, Mendelian randomization, INPH, GWAS

Wencai Wang

The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China

Abstract

Background: Idiopathic normal pressure hydrocephalus (INPH) and vascular dementia (VaD) are uncommon age-related conditions. Previous research indicated that telomere shortening is associated with aging and the emergence of age-related ailments. However, the correlation between genetically predicted telomere length (TL) and the susceptibility to INPH and VaD remains uncertain. This study seeks to examine the underlying causality of TL with the risk of INPH and VaD by employing Mendelian randomization (MR) analysis. Methods: A bidirectional MR was conducted to evaluate the potential causality of TL with the risk of INPH and VaD. Five MR methods were employed for result analysis, with the inverse variance weighted (IVW) method as the main technique. Additionally, various sensitivity analyses were performed to assess the presence of heterogeneity and pleiotropy in the study findings. Results: In the forward MR analysis, both the IVW analyses suggested an underlying causality, indicating that longer TL may correlate with a reduced incidence of INPH (IVW: OR = 0.44, 95% CI: 0.25–0.77, p = 0.004) and VaD (IVW: OR = 0.31, 95% CI: 0.12–0.82, p = 0.018). No heterogeneity or horizontal pleiotropy was observed. However, reverse MR analysis failed to uncover an underlying causality between INPH, VaD, and TL. Conclusion: There could be a potential correlation of longer TL with the decreased risk of INPH and VaD within the European population. This research offers fresh perspectives on the association of TL with the risk of INPH and VaD.

Views: 1196Downloads: 91

Issue

Vol. 1 No. 3 (2025)

Section

Computer Science and Artificial Intelligence

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Wang, W. (2025). Bidirectional Mendelian Randomization Analysis of the Association between Telomere Length and the Risk of Vascular Dementia and Idiopathic Normal Pressure Hydrocephalus. AI Med, 1(3). https://doi.org/10.71423/aimed.20251209

References

Relkin, N.; Marmarou, A.; Klinge, P.; Bergsneider, M.; Black, P. M. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005, 57, S4–16; discussion ii-v. DOI: 10.1227/01.neu.0000168185.29659.c5

Andersson, J.; Rosell, M.; Kockum, K.; Lilja-Lund, O.; Söderström, L.; Laurell, K. Prevalence of idiopathic normal pressure hydrocephalus: A prospective, population-based study. PLoS One 2019, 14, e0217705. DOI: 10.1371/journal.pone.0217705

Thavarajasingam, S. G.; El-Khatib, M.; Rea, M.; Russo, S.; Lemcke, J.; Al-Nusair, L.; Vajkoczy, P. Clinical predictors of shunt response in the diagnosis and treatment of idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis. Acta Neurochir (Wien) 2021, 163, 2641–2672. DOI: 10.1007/s00701-021-04922-z

Jaraj, D.; Agerskov, S.; Rabiei, K.; Marlow, T.; Jensen, C.; Guo, X.; Kern, S.; Wikkelsø, C.; Skoog, I. Vascular factors in suspected normal pressure hydrocephalus: A population-based study. Neurology 2016, 86, 592–599. DOI: 10.1212/wnl.0000000000002369

Israelsson, H.; Carlberg, B.; Wikkelsö, C.; Laurell, K.; Kahlon, B.; Leijon, G.; Eklund, A.; Malm, J. Vascular risk factors in INPH: A prospective case-control study (the INPH-CRasH study). Neurology 2017, 88, 577–585. DOI: 10.1212/wnl.0000000000003583

Riedel, C. S.; Milan, J. B.; Juhler, M.; Jennum, P. Sleep-disordered breathing is frequently associated with idiopathic normal pressure hydrocephalus but not other types of hydrocephalus. Sleep 2022, 45, zsab265. DOI: 10.1093/sleep/zsab265

Patel, M.; Zhang, Y.; Xiao, M. F.; Worley, P.; Moghekar, A. Neuronal pentraxin 2 correlates with neurodegeneration but not cognition in idiopathic normal pressure hydrocephalus (iNPH). Neurol Neurochir Pol 2024, 58, 47–53. DOI: 10.5603/pjnns.98212

Wang, Z.; Zhang, Y.; Hu, F.; Ding, J.; Wang, X. Pathogenesis and pathophysiology of idiopathic normal pressure hydrocephalus. CNS Neurosci Ther 2020, 26, 1230–1240. DOI: 10.1111/cns.13526

Tan, C.; Wang, X.; Wang, Y.; Wang, C.; Tang, Z.; Zhang, Z.; Liu, J.; Xiao, G. The Pathogenesis Based on the Glymphatic System, Diagnosis, and Treatment of Idiopathic Normal Pressure Hydrocephalus. Clin Interv Aging 2021, 16, 139–153. DOI: 10.2147/cia.S290709

Smith, E. E. Clinical presentations and epidemiology of vascular dementia. Clin Sci (Lond) 2017, 131, 1059–1068. DOI: 10.1042/cs20160607

Wang, X. X.; Zhang, B.; Xia, R.; Jia, Q. Y. Inflammation, apoptosis and autophagy as critical players in vascular dementia. Eur Rev Med Pharmacol Sci 2020, 24, 9601– 9614. DOI: 10.26355/eurrev_202009_23048

2015 Alzheimer's disease facts and figures. Alzheimers Dement 2015, 11, 332–384. DOI: 10.1016/j.jalz.2015.02.003

Wolters, F. J.; Ikram, M. A. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol 2019, 39, 1542–1549. DOI: 10.1161/atvbaha.119.311908

McVeigh, C.; Passmore, P. Vascular dementia: prevention and treatment. Clin Interv Aging 2006, 1, 229–235. DOI: 10.2147/ciia.2006.1.3.229

Blackburn, E. H. Structure and function of telomeres. Nature 1991, 350, 569–573. DOI: 10.1038/350569a0

Donate, L. E.; Blasco, M. A. Telomeres in cancer and ageing. Philos Trans R Soc Lond B Biol Sci 2011, 366, 76–84. DOI: 10.1098/rstb.2010.0291

López-Otín, C.; Blasco, M. A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. Cell 2013, 153, 1194–1217. DOI: 10.1016/j.cell.2013.05.039

Demanelis, K.; Jasmine, F.; Chen, L. S.; Chernoff, M.; Tong, L.; Delgado, D.; Zhang, C.; Shinkle, J.; Sabarinathan, M.; Lin, H.; et al. Determinants of telomere length across human tissues. Science 2020, 369, eaaz6876. DOI: 10.1126/science.aaz6876

Mons, U.; Müezzinler, A.; Schöttker, B.; Dieffenbach, A. K.; Butterbach, K.; Schick, M.; Peasey, A.; De Vivo, I.; Trichopoulou, A.; Boffetta, P.; et al. Leukocyte Telomere Length and All-Cause, Cardiovascular Disease, and Cancer Mortality: Results From Individual-Participant-Data Meta-Analysis of 2 Large Prospective Cohort Studies. Am J Epidemiol 2017, 185, 1317–1326. DOI: 10.1093/aje/kww210

Wang, Q.; Zhan, Y.; Pedersen, N. L.; Fang, F.; Hägg, S. Telomere Length and All-Cause Mortality: A Meta-analysis. Ageing Res Rev 2018, 48, 11–20. DOI: 10.1016/j.arr.2018.09.002

Gao, X.; Yu, X.; Zhang, C.; Wang, Y.; Sun, Y.; Sun, H.; Zhang, H.; Shi, Y.; He, X. Telomeres and Mitochondrial Metabolism: Implications for Cellular Senescence and Age-related Diseases. Stem Cell Rev Rep 2022, 18, 2315– 2327. DOI: 10.1007/s12015-022-10370-8

Honig, L. S.; Kang, M. S.; Schupf, N.; Lee, J. H.; Mayeux, R.Association of shorter leukocyte telomere repeat length with dementia and mortality. Arch Neurol 2012, 69, 1332– 1339. DOI: 10.1001/archneurol.2012.1541

Fani, L.; Hilal, S.; Sedaghat, S.; Broer, L.; Licher, S.; Arp, P. P.; van Meurs, J. B. J.; Ikram, M. K.; Ikram, M. A. Telomere Length and the Risk of Alzheimer's Disease: The Rotterdam Study. J Alzheimers Dis 2020, 73, 707– 714. DOI: 10.3233/jad-190759

Al Khleifat, A.; Iacoangeli, A.; Jones, A. R.; van Vugt, J.; Moisse, M.; Shatunov, A.; Zwamborn, R. A. J.; van der Spek, R. A. A.; Cooper-Knock, J.; Topp, S.; et al. Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data. Front Cell Neurosci 2022, 16, 1050596. DOI: 10.3389/fncel.2022.1050596

Scarabino, D.; Veneziano, L.; Mantuano, E.; Arisi, I.; Fiore, A.; Frontali, M.; Corbo, R. M. Leukocyte Telomere Length as Potential Biomarker of HD Progression: A Follow-Up Study. Int J Mol Sci 2022, 23, 13449. DOI: 10.3390/ijms232113449

Levstek, T.; Redenšek, S.; Trošt, M.; Dolžan, V.; Podkrajšek, K. T. Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson's Disease. Antioxidants (Basel) 2021, 10, 137. DOI: 10.3390/antiox10010137

Saretzki, G.; Von Zglinicki, T. Replicative aging, telomeres, and oxidative stress. Ann N Y Acad Sci 2002, 959, 24–29. DOI: 10.1111/j.1749-6632.2002.tb02079.x

Zekry, D.; Herrmann, F. R.; Irminger-Finger, I.; Graf, C.; Genet, C.; Vitale, A. M.; Michel, J. P.; Gold, G.; Krause, K. H. Telomere length and ApoE polymorphism in mild cognitive impairment, degenerative and vascular dementia. J Neurol Sci 2010, 299, 108–111. DOI: 10.1016/j.jns.2010.07.019

Birney, E. Mendelian Randomization. Cold Spring Harb Perspect Med 2022, 12, a041302. DOI: 10.1101/cshperspect.a041302

Codd, V.; Wang, Q.; Allara, E.; Musicha, C.; Kaptoge, S.; Stoma, S.; Jiang, T.; Hamby, S. E.; Braund, P. S.; Bountziouka, V.; et al. Polygenic basis and biomedical consequences of telomere length variation. Nat Genet 2021, 53, 1425–1433. DOI: 10.1038/s41588-021-00944-6

Davies, N. M.; Holmes, M. V.; Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. Bmj 2018, 362, k601. DOI: 10.1136/bmj.k601

Verbanck, M.; Chen, C. Y.; Neale, B.; Do, R. Publisher Correction: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018, 50, 1196. DOI: 10.1038/s41588-018-0164-2

Hemani, G.; Zheng, J.; Elsworth, B.; Wade, K. H.; Haberland, V.; Baird, D.; Laurin, C.; Burgess, S.; Bowden, J.; Langdon, R.; et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018, 7, e34408. DOI: 10.7554/eLife.34408

Burgess, S.; Thompson, S. G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 2017, 32, 377–389. DOI: 10.1007/s10654-017-0255-x

Wu, F.; Huang, Y.; Hu, J.; Shao, Z. Mendelian randomization study of inflammatory bowel disease and bone mineral density. BMC Med 2020, 18, 312. DOI: 10.1186/s12916-020-01778-5

Kamat, M. A.; Blackshaw, J. A.; Young, R.; Surendran, P.; Burgess, S.; Danesh, J.; Butterworth, A. S.; Staley, J. R. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics 2019, 35, 4851–4853. DOI: 10.1093/bioinformatics/btz469

Reeves, B. C.; Karimy, J. K.; Kundishora, A. J.; Mestre, H.; Cerci, H. M.; Matouk, C.; Alper, S. L.; Lundgaard, I.; Nedergaard, M.; Kahle, K. T. Glymphatic System Impairment in Alzheimer's Disease and Idiopathic Normal Pressure Hydrocephalus. Trends Mol Med 2020, 26, 285–295. DOI: 10.1016/j.molmed.2019.11.008

Xiao, H.; Hu, F.; Ding, J.; Ye, Z. Cognitive Impairment in Idiopathic Normal Pressure Hydrocephalus. Neurosci Bull 2022, 38, 1085–1096. DOI: 10.1007/s12264-022-00873-2

Leinonen, V.; Koivisto, A. M.; Savolainen, S.; Rummukainen, J.; Sutela, A.; Vanninen, R.; Jääskeläinen, J. E.; Soininen, H.; Alafuzoff, I. Post-mortem findings in 10 patients with presumed normal-pressure hydrocephalus and review of the literature. Neuropathol Appl Neurobiol 2012, 38, 72–86. DOI: 10.1111/j.1365-2990.2011.01195.x

Papageorgakopoulou, M. A.; Bania, A.; Lagogianni, I. A.; Birmpas, K.; Assimakopoulou, M. The Role of Glia Telomere Dysfunction in the Pathogenesis of Central Nervous System Diseases. Mol Neurobiol 2024, 61, 5868–5881. DOI: 10.1007/s12035-024-03947-6

Flanary, B. E.; Sammons, N. W.; Nguyen, C.; Walker, D.; Streit, W. J. Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res 2007, 10, 61–74. DOI: 10.1089/rej.2006.9096

Topiwala, A.; Nichols, T. E.; Williams, L. Z. J.; Robinson, E. C.;Alfaro-Almagro, F.; Taschler, B.; Wang, C.; Nelson, C. P.; Miller, K. L.; Codd, V.; et al. Telomere length and brain imaging phenotypes in UK Biobank. PLoS One 2023, 18, e0282363. DOI: 10.1371/journal.pone.0282363

Jaskelioff, M.; Muller, F. L.; Paik, J. H.; Thomas, E.; Jiang, S.; Adams, A. C.; Sahin, E.; Kost-Alimova, M.; Protopopov, A.; Cadiñanos, J.; et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 2011, 469, 102–106. DOI: 10.1038/nature09603

Sagris, M.; Theofilis, P.; Antonopoulos, A. S.; Tsioufis, K.; Tousoulis, D. Telomere Length: A Cardiovascular Biomarker and a Novel Therapeutic Target. Int J Mol Sci 2022, 23, 16010. DOI: 10.3390/ijms232416010

Deng, Z.; Wang, H.; Huang, K.; Li, Y.; Ran, Y.; Chen, Y.; Zhou, L. Association between vascular risk factors and idiopathic normal pressure hydrocephalus: a Mendelian randomization study. J Neurol 2023, 270, 2724–2733. DOI: 10.1007/s00415-023-11604-6

Ecay-Torres, M.; Estanga, A.; Tainta, M.; Izagirre, A.; Garcia-Sebastian, M.; Villanua, J.; Clerigue, M.; Iriondo, A.; Urreta, I.; Arrospide, A.; et al. Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults. Neurology 2018, 91, e217–e226. DOI: 10.1212/wnl.0000000000005824

Rabin, J. S.; Nichols, E.; La Joie, R.; Casaletto, K. B.; Palta, P.; Dams-O'Connor, K.; Kumar, R. G.; George, K. M.; Satizabal, C. L.; Schneider, J. A.; et al. Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. Brain 2022, 145, 2823–2833. DOI: 10.1093/brain/awac178

von Zglinicki, T.; Serra, V.; Lorenz, M.; Saretzki, G.; Lenzen-Grossimlighaus, R.; Gessner, R.; Risch, A.; Steinhagen-Thiessen, E. Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor? Lab Invest 2000, 80, 1739–1747. DOI: 10.1038/labinvest.3780184

Chen, C.; Upton, C.; Braidy, N.; Khalil, J.; Fang, Z. M.; Xu, Y. H.; Chan, D. K. Association between leukocyte telomere length and vascular dementia and cancer mortality in an elderly population. J Am Geriatr Soc 2014, 62, 1384–1386. DOI: 10.1111/jgs.12910

Löf-Ohlin, Z. M.; Hagnelius, N. O.; Nilsson, T. K. Relative telomere length in patients with late-onset Alzheimer's dementia or vascular dementia. Neuroreport 2008, 19, 1199–1202. DOI: 10.1097/WNR.0b013e3283089220

Kalaria, R. N. The pathology and pathophysiology of vascular dementia. Neuropharmacology 2018, 134, 226– 239. DOI: 10.1016/j.neuropharm.2017.12.030

Suchy-Dicey, A. M.; Muller, C. J.; Madhyastha, T. M.; Shibata, D.; Cole, S. A.; Zhao, J.; Longstreth, W. T., Jr.; Buchwald, D. Telomere Length and Magnetic Resonance Imaging Findings of Vascular Brain Injury and Central Brain Atrophy: The Strong Heart Study. Am J Epidemiol 2018, 187, 1231–1239. DOI: 10.1093/aje/kwx368

Wikgren, M.; Karlsson, T.; Söderlund, H.; Nordin, A.; Roos, G.; Nilsson, L. G.; Adolfsson, R.; Norrback, K. F. Shorter telomere length is linked to brain atrophy and white matter hyperintensities. Age Ageing 2014, 43, 212– 217. DOI: 10.1093/ageing/aft172

Staffaroni, A. M.; Tosun, D.; Lin, J.; Elahi, F. M.; Casaletto, K. B.; Wynn, M. J.; Patel, N.; Neuhaus, J.; Walters, S. M.; Epel, E. S.; et al. Telomere attrition is associated with declines in medial temporal lobe volume and white matter microstructure in functionally independent older adults. Neurobiol Aging 2018, 69, 68– 75. DOI: 10.1016/j.neurobiolaging.2018.04.021

Li, J.; Feng, C.; Li, L.; Yang, S.; Chen, Y.; Hui, R.; Zhang, M.; Zhang, W. The association of telomere attrition with first-onset stroke in Southern Chinese: a case-control study and meta-analysis. Sci Rep 2018, 8, 2290. DOI: 10.1038/s41598-018-20434-w

Zhang, W.; Chen, Y.; Wang, Y.; Liu, P.; Zhang, M.; Zhang, C.; Hu, F. B.; Hui, R. Short telomere length in blood leucocytes contributes to the presence of atherothrombotic stroke and haemorrhagic stroke and risk of post-stroke death. Clin Sci (Lond) 2013, 125, 27–36. DOI: 10.1042/cs20120691

Fernández-Alvira, J. M.; Fuster, V.; Dorado, B.; Soberón, N.; Flores, I.; Gallardo, M.; Pocock, S.; Blasco, M. A.; Andrés, V. Short Telomere Load, Telomere Length, and Subclinical Atherosclerosis: The PESA Study. J Am Coll Cardiol 2016, 67, 2467–2476. DOI: 10.1016/j.jacc.2016.03.530

Cheng, F.; Carroll, L.; Joglekar, M. V.; Januszewski,A. S.; Wong, K. K.; Hardikar, A. A.; Jenkins, A. J.; Ma, R. C. W. Diabetes, metabolic disease, and telomere length. Lancet Diabetes Endocrinol 2021, 9, 117–126. DOI: 10.1016/s2213-8587(20)30365-x

Sato, M.; Wai, K. M.; Itoh, K.; Yang, Y.; Uchikawa, Y.; Ito, Y.; Nakaji, S.; Ihara, K. Does the Protective Effect of Zinc on Telomere Length Depend on the Presence of Hypertension or Type 2 Diabetes? Results from the Iwaki Health Promotion Project, Japan. Nutrients 2023, 15. DOI: 10.3390/nu15204373

Zhang, B.; Chen, L.; Swartz, K. R.; Bruemmer, D.; Eum, S. Y.; Huang, W.; Seelbach, M.; Choi, Y. J.; Hennig, B.; Toborek, M. Deficiency of telomerase activity aggravates the blood-brain barrier disruption and neuroinflammatory responses in a model of experimental stroke. J Neurosci Res 2010, 88, 2859–2868. DOI: 10.1002/jnr.22450

Article Sidebar

Main Article Content

Abstract

Article Details

Issue

Section

How to Cite

References

Similar Articles